Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECT ...

Exhibit 99.1 argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis VYVGART is the first neonatal Fc receptor (FcRn) blocker approved in the UK for the treatment of adults living with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive 68% of anti-AChR antibody positive gMG patients treated with VYVGART were responders (n=44/65) on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale compared with 30% of patient ...

argenx SE (NASDAQ:ARGX) Q4 2022 Earnings Conference Call March 2, 2023 8:30 AM ET Company Participants Beth DelGiacco - VP Corporate Communications and IR Tim Van Hauwermeiren - CEO Karl Gubitz - CFO Keith Woods - COO Conference Call Participants Tazeen Ahmad - Bank of America Securities Rajan Sharma - Goldman Sachs Thomas Smith - SVB Securities Brendan Smith - Cowen Yatin Suneja - Guggenheim Partners Myles Minter - William Blair Manos Mastorakis - Deutsche Bank Alex Nackenoff - Raymond James Allison Bratze ...

Fourth Quarter and Full Year 2022 Financial Results and Business Update March 2, 2023 Forward Looking Statements This presentation has been prepared by argenx se ("argenx" or the "company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or the company or any director, employee, agent, or adviser of the company. This presentation does not purport to be all-inclusi ...

argenx SE (NASDAQ:ARGX) Q2 2022 Earnings Conference Call July 28, 2022 8:30 AM ET Company Participants Beth DelGiacco - VP Corporate Communications and IR Tim Van Hauwermeiren - CEO Karl Gubitz - CFO Keith Woods - COO Conference Call Participants Danielle Brill - Raymond James Yaron Werber - Cowen Yatin Suneja - Guggenheim Partners Derek Archila - Wells Fargo Allison Bratzel - Piper Sandler Akash Tewari - Jefferies Matthew Harrison - Morgan Stanley Tazeen Ahmad - Bank of America Securities Thomas Smith - SV ...

argenx SE (NASDAQ:ARGX) Q1 2022 Earnings Conference Call May 5, 2022 8:30 AM ET Corporate Participants Beth DelGiacco - VP Corporate Communications and Investor Relations Tim Van Hauwermeiren - Chief Executive Officer Luc Truyen - Chief Medical Officer Karl Gubitz - Chief Financial Officer Keith Woods - Chief Operating Officer Conference Call Participants Yatin Suneja - Guggenheim Matthew Harrison - Morgan Stanley Tazeen Ahmad - Bank of America Akash Tewari - Jefferies Yaron Werber - Cowen James Gordon - JP ...